CORRELATION OF MULTIPARAMETRIC MRI (MPMRI) WITH PSA IN ASSESSMENT OF RESPONSE TO COMBINED HDR PROSTATE BRACHYTHERAPY AND EXTERNAL BEAM RADIOThERAPY FOR UPPER TIER INTERMEDIATE AND HIGH-RISK PROSTATE CANCER

Juanita Crook1, Francois Bachand1, Sylla Chang2, Deidre Batchelor2, Matt Schmid1

1University of British Columbia, Kelowna, BC
2University of British Columbia, Vancouver, BC

Purpose: mpMRI has been demonstrated to be very useful for staging and surveillance of localized prostate cancer. The PI-Rads system has been developed for scoring the malignant probability of lesions. We identified the dominant intra-prostatic lesion (DIL) on mpMRI for intermediate- and high-risk prostate cancer patients treated with androgen suppression (6-24 months) and 15 months after radiation to determine if the PI-Rads system could be useful in assessing the radiologic response to treatment.

Methods and Materials: From August 2012 to July 2013, 26 patients with predominantly unilateral disease consented to a University Ethics-approved Phase 2 study of selective dose escalation. HDR brachytherapy was performed in weeks 1 and 3 of treatment, each delivering one fraction of 10 Gy to the whole prostate. External beam consisted of 46 Gy/23 fractions starting within one week after the first HDR fraction. Pre-treatment T2 FSE images were obtained using 1.5T endorectal MRI in transverse, sagittal and coronal planes followed by Dynamic Contrast Enhancement after injection of gadolinium. Apparent Diffusion Coefficient maps were calculated. Following image registration, the DIL was transposed to the intra-operative TRUS with source-delivery catheters in place for the purpose of a 25% escalation in dose. At median 15.6 mo (12-18.6) mp MRI was repeated in the 16 patients who did not receive ADT.

Results: Twenty-five out of 26 patients initially had a visible DIL. Mean pre-treatment PI-Rads score was 4.1 (range 3-5 for region of biopsy-proven disease). Coverage of the DIL was excellent with a median of 97% receiving the planned escalation of 25%. Mean PI-Rads score in follow up mpMRI in 16 patients at a median of 15.6 mo was 2.7. Median PSA was 0.2. Only two MRI’s still received a PI-Rads score of 4 and PSA for these two patients was 1.4 and 1.2; all others were < 0.5 ng/ml. Current PSA is 1.1 and 1.02 for these two patients and biopsies show scattered foci of residual tumour with marked RT effect.

Conclusions: mpMRI using the PI-Rads classification may be adjunctive to PSA to assess response to radiation. Optimal timing and correlation with biopsy findings needs to be determined in a larger population.

ACUTE AND LATE TOXICITY IN HIGH-RISK PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN SUPPRESSION AND HYPFRAC Fractionated Radiotheraphy (HypRT) TO THE PROSTATE AND PELVIC NODES

Sergio Faria1, Mariana Petrucelli2, Fabio Cory1, Marie Duclos1, Luis Souhami1

1McGill University Health Centre, Montreal, QC
2Radiation Oncology, Rio de Janeiro, Brazil

Purpose: Moderate HypoRT is an acceptable option in the curative treatment of prostate cancer. Among different fractionation regimens, the dose of 60 Gy in 20 fractions was used in prospective randomized trials (PROFIT, CHIP), mainly for low and intermediate-risk patients where the PTV is only the prostate(+/-) seminal vesicle(SV) but not the pelvic nodes. We report here the acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and HypoRT to the prostate and pelvic nodes with doses of 60 Gy to prostate and 44 Gy to the pelvic nodes given in 20 fractions with a simultaneous integrated boost.

Methods and Materials: Localized high-risk prostate cancer patients (T3, or PSA>20ng/ml, or GS>8) were treated with androgen suppression (6-24 months) started 2-3 months before HypoRT. Radiotherapy was delivered using IMRT with daily IGRT. Constrains for organs at risk were the same of RTOG-0126 corrected with the linear-quadratic model (alpha=8mg2Gy). A dose of 44 Gy (2.2 Gy/fraction) was delivered to the pelvic nodes and 60 Gy (3 Gy/fraction) to the prostate (+/- SV) with a concomitant boost in 20 fractions (4 weeks). Cone beam CT was used daily to guide the treatment accuracy. Acute and late toxicities were assessed prospectively and scored using the National Cancer Institute common Terminology Criteria for Adverse Events, version3.0. Biochemical failure was determined using the Phoenix definition.

Results: 105 patients treated between September/2010 and November/2013 were reviewed. Median age, median initial PSA and T stage were 72 years (52-84), PSA=14(1.8-108), T1c = 36 and T3= 22 patients. Median follow up is 35 months (12-61). Acute GI toxicity (%) was as follows: Grade 0 = 38, Grade 1 = 45, Grade 2 = 16 and Grade 3 = 1. Acute GU toxicity was Grade 0 = 50, Grade 2 = 14 and Grade 3 = 3. The worst late GI toxicity(%) was, as follows: Grade 0 = 74 Grade 1 = 19, Grade 2/3 = 7. The worst late GU toxicity(%) was: Grade 0 = 77, Grade 1 = 15, Grade 2/3 = 8. There was no Grade>3 toxicity. At the last follow-up the incidences of grade 2 late GU and GI toxicity were 5% and 3%, respectively (no residual grade >2 toxicity). At this limited follow-up, 13 patients developed biochemical failure at a median time to failure of 12 months without showing evidence of metastatic disease. Three patients died so far, and one from prostate cancer.

Conclusion: Androgen suppression with moderate HypoRT IMRT and IGRT to the prostate (60Gy) and pelvic nodes (44Gy) delivered with simultaneous integrated boost in 4 weeks (20 fractions) is feasible and well tolerated. Further follow-up is needed to establish long-term PSA control rates and survival outcomes.

A POPULATION-BASED STUDY OF RADIATION THERAPY REFERRAL AND TREATMENT PRACTICES POST-PROSTATECTOMY OVER A DECADE (2003-2012)

Chunzi Jenny Jin1, Timothy Hanna2, Earl Cook3, Qun Miao2, Michael Brundage2

1Harvard School of Public Health, Boston, MA
2Queen’s University, Kingston, ON
3Harvard T.H. Chan School of Public Health, Boston, MA

Purpose: Adjuvant radiotherapy (ART) post-radical prostatectomy (RP) has been shown to benefit patients with pathologic T3 or marginal positive prostate cancer. Early salvage radiotherapy (SRT) is commonly practiced, but it remains unclear if SRT confers equivalent outcomes to ART. Recent Ontario Practice Guidelines recommend referral to radiation oncology (RO) within six months of RP to discuss ART and SRT. Our objectives were to describe patterns of care over time to (1) assess post-RP referral patterns to RO; (2) describe ART and SRT utilization; and (3) compare time trends before and after seminal trials and guidelines were published, and in doing so, provide indications of access to quality care.

Methods and Materials: This was a retrospective cohort study. Electronic clinic visit and RT treatment records were linked to the population-based Ontario Cancer Registry. The study population included all prostate cancer cases treated with RP in Ontario January 1, 2003 - November 30, 2012. ART was defined as curative RT within six months of RP and SRT was 6 - 24 months post-RP. Changes in RO referral and RT rates over time were statistically analyzed using the Cochran-Mantel-Haenszel Chi-Square test.

Results: Over the study period, 30,447 prostate cancer patients received RP and 15.2% saw an RO within six months of RP. This proportion doubled between 2003 and 2012 (from 10.7% in 2003-2004 to 21.7% in 2011-2012, p < 0.001 for trend). The annual percentage change was largest 2009-2011 (3.4% increase). In comparison, the proportion seen within 24 months of RP remained stable at 32.3% ± 1.4%. Amongst the 4,641 patients seen by an RO within 6 months of RP for consideration of ART or SRT, the proportion receiving ART remained relatively constant at 51.0% ± 3.0%. Commensurate with RO referral trends, there was, as follows: Grade 0 = 74 Grade 1 = 19, Grade 2/3 = 7. The worst late GU toxicity(%) was: Grade 0 = 77, Grade 1 = 15, Grade 2/3 = 8. There was no Grade>3 toxicity. At the last follow-up the incidences of grade 2 late GU and GI toxicity were 5% and 3%, respectively (no residual grade >2 toxicity). At this limited follow-up, 13 patients developed biochemical failure at a median time to failure of 12 months without showing evidence of metastatic disease. Three patients died so far, and one from prostate cancer.

Conclusion: Androgen suppression with moderate HypoRT IMRT and IGRT to the prostate (60Gy) and pelvic nodes (44Gy) delivered with simultaneous integrated boost in 4 weeks (20 fractions) is feasible and well tolerated. Further follow-up is needed to establish long-term PSA control rates and survival outcomes.